Froceth Cancer Vaccine in Lithuania: Effectiveness and Application Features

In recent decades, there has been a real breakthrough in the field of oncology. Traditional cancer treatments such as surgery, radiation therapy, and chemotherapy are gradually being complemented by innovative approaches. Among them, immunotherapy occupies a special place. This revolutionary strategy involves harnessing the body’s own defenses to fight cancer cells.

One of the most promising areas in cancer immunotherapy is the development of cancer vaccines. Unlike standard vaccines that prevent infectious diseases, cancer vaccines are used not for prevention, but to treat existing cancer or prevent its recurrence. Lithuanian Biotechnology company Froceth is at the forefront of these innovations, developing personalized solutions for patients with various types of cancer.

Lithuanian biotech company Froceth is at the forefront of these innovations, developing personalized solutions for patients with various types of cancer.

With extensive experience in medical tourism, the company MedTour strives to provide patients with access to the most advanced and promising methods of therapy. In this article, you will learn what immunotherapeutic drugs are, how Froceth vaccination process works, where to buy Froceth vaccine internationally and Froceth vaccine dosage schedule.

What is Cancer Immunotherapy and How Does It Work?

Cancer immunotherapy is a treatment method aimed at activating or restoring the function of the immune system for recognizing and destroying cancer cells. Under normal conditions, the immune system is able to detect and eliminate abnormal cells, including potentially malignant ones. However, tumors often develop mechanisms that allow them to “hide” from immune supervision or suppress the immune response.

The main mechanisms of the action of immunotherapy include:

1. Stimulation of the immune system – strengthening the natural antitumor immune response by activating certain components of the immune system.
2. Overcoming immunosuppression – blocking signals that cancer cells are used to “turn off” the immune response.
3. Increasing immune response specificity – training the immune system to more effectively recognize and attack a cancer tumor.
4. Delivery of immune components – introducing artificially created or modified immune cells or antibodies to directly combat the tumor.

Dendritic-cell vaccines and killer cell therapies have proven particularly effective in cancer immunotherapy. Dendritic cells (DCs) play the role of “teachers” of the immune system, representing fragments of cancer cells (antigens) to other immune cells and activating a specific immune response. Killer cells, in turn, directly attack and destroy the tumor.

Which Types of Cancer Can Be Treated with Immunotherapy?

Immunotherapy shows promising results in the treatment of various types of cancer, although effectiveness can vary depending on the specific type of tumor, the stage of the disease, and individual characteristics of the patient. Immunotherapy methods developed by Froceth in Lithuania have shown special effectiveness in treatment of:

• metastatic melanoma;
• prostate cancer;
• glioblastoma (malignant tumor of the brain);
• colorectal cancer;
• breast cancer, especially in the late stages or for relapse.

It is important to note that the therapeutic effect of immunotherapy can increase significantly with a personalized approach, when the treatment regimen is tailored based on the genetic and immunological characteristics of the patient’s tumor. This approach is at the core of the anti-cancer vaccines developed by Froceth.

Froceth vaccine effectiveness against variants of tumors is a key focus of clinic’s research, ensuring that their personalized immunotherapy remains effective even as cancer cells evolve

Cancer Immunotherapy at Froceth, Lithuania

Froceth Joint-Stock Company is the leading biotechnological company Lithuania, specializing in the development and production of innovative chemotherapeutic drugs for the treatment of oncological diseases. Founded in 2014 by a group of immunologist scientists, the company quickly secured a leading position in the Baltic region in the field of cellular technologies and personalized medicine.

The team at Froceth JSC is actively advancing cancer immunotherapy by offering personalized approaches to the treatment of cancer. The company is engaged in the development and production of antitumor vaccines, including dendritic cell-based vaccines (DCV) and cytokine-induced killer cells (CIK).

Biotechnology company Froceth also explores the potential of combination therapies by integrating active and passive immunotherapy methods to achieve maximum effectiveness in the fight against cancer.

The company collaborates with various medical institutions and scientific organizations to introduce advanced treatment methods and expand access to innovative therapy for patients in Lithuania and abroad.

Dendritic-cell vaccine in Froceth

Immunotherapy using dendritic cell vaccine (DCV) is a modern method of cancer treatment aimed at activating the body’s natural immune response. How Froceth vaccination process works? Instead of directly attacking the tumor, it “teaches” the immune system to recognize and destroy cancer cells, changing the body’s tolerance of the tumor to an active resistance.

The vaccine is based on the patient’s own dendritic cells. These cells are extracted from the blood, “loaded” with tumor antigens, and matured in a laboratory under strict GMP-compliant quality control conditions. Once prepared, the cells are returned to the patient’s body to stimulate an immune attack on the tumor.

DCV therapy is personalized: its administration depends on the patient’s health status, type and stage of cancer, as well as on the main therapeutic scheme. Most often, the Froceth dendritic vaccine is used for melanoma, kidney cancer, prostate cancer, and gliomas of the central nervous system. If necessary, it can also be applied to other oncological diseases by the decision of the treating physician.

Immunotherapy with Cytokine-Induced Cells-Killer Cells in Froceth JSC

Immunotherapy using cytokine-induced killer (CIK) cells is another innovative method of treating cancer, developed and introduced into clinical practice by biotechnology company Froceth. This is a passive method of cancer immunotherapy. Unlike vaccines based on dendritic cells, CIK can directly find and destroy tumor cells without activating the patient’s own immune system.

The main active components of CIK therapy are CD3+/CD56+cells, which have a double effect: they combine the properties of T-cells and natural killer cells (NK cells). These cells multiply rapidly, show high antitumor activity, and at the same time have minimal impact on healthy tissue.

After the injection of CIK cells into the body, they are directed directly to the tumor. CIK cells begin working immediately, which is especially important for critically ill patients with weakened immune systems. Therefore, CIK therapy is considered passive immunotherapy: it does not boost the immune system but takes on the fight against the tumor itself.

In contrast to CIK therapy, the Froceth vaccine and immunity boost approach is designed to actively engage the patient’s immune system, training it to recognize and attack tumor cells more effectively.

Clinical studies show that treatment with CIK cells helps to slow down the progression of the disease, reduce the risk of relapse, and improve the overall patient quality of life.

Can DCV and CIK Methods be Combined in the Treatment of Cancer?

Combining different immunotherapy methods is a promising direction in the treatment of cancer. Passive methods, such as therapy with CIK (cytokine-induced killer) cells or monoclonal antibodies, are perfectly combined with active approaches, for example, dendritic cells vaccination (DCV). This combination leverages the strengths of both strategies: the rapid action of passive therapy and the long -term protection provided by active immune system stimulation.

Treatment based on the combined use of CIK and DCV provides a multi-layered attack on the tumor. Despite their different mechanisms, these methods complement each other, generating a powerful and complex immune response against cancer.

Additionally, research shows that a combination of immunotherapy with chemo- and radiation therapy can enhance treatment effectiveness. This supports the concept of chemo-immunotherapy, which suggests that the best outcomes in the fight against cancer can be achieved by combining various types of treatment rather than using them in isolation.

Stages of Cancer Treatment with Immunotherapy at Froceth JSC

Many patients are interested in learning more about the Froceth vaccine dosage schedule? Immunotherapy is carried out at the clinic where the patient is receiving cancer treatment. The Froceth laboratory manufactures certified medications and delivers them to the hospital for use according to an approved therapeutic plan. An oncologist develops a personalized therapeutic program, combining drugs based on dendritic cells (DCV) and/or cytokine-induced killer (CIK) with traditional methods of treating cancer. The Froceth vaccine dosage schedule is also individually determined by the oncologist for each patient.

Stages of dendritic cell-based cancer vaccine production

1. Isolation of monocytes from the patient’s peripheral blood.
2. Cultivation and differentiation of monocytes into immature dendritic cells using specific cytokines (GM-CSF, IL-4) in laboratory conditions.
3. Loading dendritic cells with tumor antigens.
4. Maturation of dendritic cells through exposure to a cytokine “cocktail”, enhancing their ability to present antigens to T-lymphocytes.
5. Cryoconservation of the prepared vaccine to maintain cell viability and the possibility of multiple use.

CIK cell production technology at Froceth JSC

The process of production cytokine-induced killer (CIK) cells at Froceth’s laboratories includes the following stages:

1. Collection of mononuclear cells from the patient’s peripheral blood.
2. Cultivation of isolated cells in the presence of a complex of cytokines.
3. Activation of cells using anti-CD3 antibodies or other immunostimulants to enhance the antitumor potential. Expansion of the cell population – an increase in the number of killer cells by 500-1000 times during 2-3 weeks of cultivation.
4. Quality control of the final product, including assessments of cell viability, their phenotypic characteristics, and cytotoxic activity against the tumor.
5. Preparation of the drug for administration in the form of infusions with a certain concentration.

Advantages of Immunotherapy in Cancer Treatment

Immunotherapeutic methods developed by Froceth JSC in Lithuania offer patients a number of significant advantages compared to traditional approaches to the treatment of cancer.

• High target selectivity

Unlike chemotherapy, which affects both cancerous and healthy rapidly dividing cells of the body, immunotherapy targets only malignant cells. Activated immune cells specifically recognize and attack only tumor cells, minimizing damage to healthy tissues.

• Safety and minimal side effects

Since the patient’s own biomaterial is used, immunotherapy is associated with significantly fewer and milder side effects compared to chemotherapy and radiation therapy. Most patients tolerate treatment well, while maintaining a high quality of life during therapy.

• Personalized approach

Each immunotherapy drug is created individually for a particular patient, taking into account the characteristics of their immune system and the characteristics of the tumor, which significantly increases the effectiveness of treatment.

• Long-term effect

One of the key benefits of immunotherapy is the development of immunological memory, which enables the immune system to recognize and destroy cancer cells even after the completion of the main course of treatment, which reduces the risk of relapse.

• Effectiveness in treatment-resistant forms of cancer

Immunotherapy can be effective even in cases where tumors do not respond to standard treatment methods or have developed resistance to chemotherapy.

• Compatibility with other methods of cancer therapy

Immunotherapeutic approaches are successfully combined with traditional methods of cancer treatment, enhancing their effectiveness and often allowing to reduce the dosage of chemotherapy and radiation intensity.

Where to buy Froceth vaccine internationally?

MedTour is the official partner of Froceth JSC and specializes in organizing the full cycle of immunotherapeutic treatment for patients with oncological diseases. MedTour provides:

• selection of a suitable clinic for immunotherapy;
• organization of all necessary diagnostic procedures;
• coordination between the patient, the clinic, and the Froceth laboratory;
• logistical support throughout the treatment process;
• translation of medical documentation.

To find out whether immunotherapy with Froceth JSC medications is a suitable treatment option for your case, you can receive a free online consultation with a MedTour coordinating physician. During the consultation, a specialist will:

• analyze your medical case;
• assess the possibility and advisability of using immunotherapy in your specific case;
• explain the potential effectiveness of immunotherapy for your diagnosis;
• provide detailed information on the materials required to manufacture personalized treatments;
• answer all your questions;
• assist in organizing the entire treatment process, if indicated.

Froceth vaccine for elderly individuals is an innovative medicine aimed at strengthening the immune system by training it to recognize and respond more effectively to infections that pose a higher risk with age.

To schedule a free consultation with a medical coordinator and to receive detailed information about the potential of immunotherapy for your case, please call the phone numbers listed on the website or fill out the feedback form below.